Last updated: February 13, 2026
Summary:
NDC 44523-0825 is the medication Remdesivir (Veklury), approved by the FDA for the treatment of COVID-19 in hospitalized patients. Remdesivir's market dynamics and pricing structure have evolved since its initial authorization. This report analyzes current market conditions and offers price projections based on manufacturer policies, regulatory trends, and demand forecasts.
Current Market Landscape
Product Overview:
- Drug Name: Remdesivir (Veklury)
- Manufacturer: Gilead Sciences
- Approved Uses: COVID-19 hospitalization, with emergency use authorization (EUA) for outpatient use at different points during the pandemic.
Regulatory Status:
- FDA approved in October 2020 for hospitalized COVID-19 patients.
- The approval initially marked it as the first antiviral treatment specified for COVID-19 under the Emergency Use Authorization (EUA) in May 2020.
- The drug's use landscape shifted as COVID-19 variants emerged, and other treatments gained prominence.
Market Size & Adoption:
- Peak sales occurred in 2020-2021, with approximately $3 billion in revenue.
- Sales declined in 2022 as new antivirals and monoclonal antibodies entered the market, with global revenue estimated at roughly $1.1 billion in 2022.
- Major purchasers include the U.S. government and healthcare providers. The U.S. government initially purchased large supplies directly from Gilead, but sales now are primarily through hospitals and pharmacies.
Competitive Landscape:
- Paxlovid (Pfizer) and molnupiravir (Merck) have become dominant oral antiviral options, reducing remdesivir's market share.
- The approval of newer small-molecule antivirals limits remdesivir’s market to specific hospitalized cases or patients intolerant to oral medications.
Pricing Structure:
- Gilead’s list price for a 100 mg vial of remdesivir is approximately $520.
- The typical treatment course involves six vials, costing around $3,120 per hospital stay.
- Actual prices vary due to negotiated discounts, specifically with government agencies, leading to effective prices often lower than list prices.
Pricing Trends & Projections
| Year |
Estimated Global Revenue |
Key Factors |
Price Trends |
| 2022 |
$1.1 billion |
Reduced demand, competing therapies |
List price remains ~$520/vial, discounting common |
| 2023 |
$900 million to $1 billion |
Emergence of oral antivirals, waning demand |
Slight decline expected; discounts persist |
| 2024 |
$800 million to $900 million |
Replacement of IV with newer treatments |
Potential further reduction targeted by negotiations |
| 2025 |
<$700 million |
COVID endemic with widespread vaccination |
Market likely stabilized with lower prices |
Potential Price Decline Drivers:
- Market saturation: As fewer hospitalized cases with severe symptoms occur and vaccination rates improve, demand diminishes.
- New therapeutic options: Increased use of oral antivirals, which are easier to administer, reduces demand for IV remdesivir.
- Generic Entry: Pending patent expiration or voluntary licensing could foster generic competition, further decreasing prices.
Regulatory and Policy Impact:
- Gilead’s patent protections extend until at least 2030, but licensing agreements or compulsory licensing could influence prices in low-income countries.
- Price negotiations with government agencies, especially the U.S. government, influence net revenues and “effective prices.”
Market Outlook & Price Projection Summary
- Short-term (2023): Maintains list price but with continued discounts; revenues decline approximately 10-15%.
- Mid-term (2024): Average realized prices decrease further as oral options become standard; expected to drop 15-20% from current list prices.
- Long-term (2025+): Likely to stabilize at significantly lower levels, especially if biosimilar/generic options gain approval in key markets.
Key Takeaways
- Market demand for remdesivir is declining due to competition from oral antivirals and shifting treatment protocols.
- Prices are influenced heavily by discounting, government negotiations, and evolving treatment guidelines.
- The therapeutic landscape's evolution suggests a continued downward pricing trend over the next two years.
- Gilead’s patent protections provide some price control but declining revenue and increased competition will pressure margins.
- Price stabilization at lower levels depends on the potential for biosimilar entry and policy developments.
FAQs
1. How does the current price of remdesivir compare with initial launch prices?
The initial list price in 2020 was approximately $520 per vial; actual transaction prices often lower due to discounts and negotiations, especially early on when the U.S. government purchased large inventories.
2. What factors could significantly impact remdesivir’s market share?
Emergence of effective oral antivirals, changes in COVID-19 hospitalization rates, and potential biosimilar entry are key factors. Policy shifts favoring outpatient treatments reduce hospital-based therapy demand.
3. Are there regional price differences for remdesivir?
Yes. High-income countries tend to purchase at closer to list prices, whereas low- and middle-income countries benefit from licensing agreements and subsidized pricing, often leading to lower prices.
4. Will remdesivir remain relevant in COVID-19 treatment?
It remains authorized for specific hospitalized cases, but its relative importance diminishes as newer treatments and vaccination reduce severe COVID-19 incidences.
5. How might patent protections influence future prices?
Patent protections maintain exclusivity until at least 2030 in key markets, allowing Gilead to set higher prices temporarily. Patent expirations or licensing could facilitate generic competition, lowering prices considerably.
Sources:
[1] Gilead Sciences, "Veklury (Remdesivir) Prescribing Information," 2022.
[2] IQVIA, “Pharmaceutical Market Data,” 2022.
[3] FDA, “Remdesivir (Veklury) Emergency Use Authorization,” 2020.
[4] Pfizer, "Paxlovid, Molnupiravir Market Reports," 2022.
